Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries (PACCOCATH_F)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00472472
Recruitment Status : Completed
First Posted : May 11, 2007
Last Update Posted : June 30, 2010
Information provided by:
University Hospital, Saarland

Brief Summary:
The PACCOCATH FEM study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in prevention of restenosis after femoropopliteal angioplasty.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: paclitaxel coated balloon catheter (device with drug) Phase 1 Phase 2

Detailed Description:

Background: Treatment of patients with peripheral arterial disease (PAD) in the femoropopliteal arteries by percutaneous intervention is still limited by high rates of restenosis. The aim of the present study is to evaluate the efficacy and safety of a novel method of short time local drug delivery based on a paclitaxel-coated balloon in femoropopliteal arteries.

Methods and results: The double-blind and randomized study enrolled n=79 patients with occlusion or stenosis of femoropopliteal arteries. Inclusion criteria were clinical Rutherford stage 1-5, occlusion or hemodynamic relevant stenosis (≥ 70 % diameter) of femoropopliteal arteries and successful guiding wire recanalization. The primary endpoint was the late lumen loss after 6 months follow-up as seen in angiography. Secondary endpoints included the rate of restenosis (a binary variable), change of ankle brachial index (ABI), rutherford class and major adverse events.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 87 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I)
Study Start Date : April 2004
Actual Primary Completion Date : July 2007
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 1
Device: paclitaxel coated balloon catheter (device with drug)
PTA vs Paccocath
Active Comparator: 2
PTA with Paccocath
Device: paclitaxel coated balloon catheter (device with drug)
PTA vs Paccocath

Primary Outcome Measures :
  1. angiographic late lumen loss [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. binary restenosis rate; major adverse events [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Rutherford stage 1, 2, 3, 4 oder 5
  • Occlusion or Stenosis of Superficial femoral and/or popliteal artery
  • Successful guide wire passage of the lesion
  • Patient suitable of vascular surgery in case of complication
  • Written consent
  • Patient is willing to take part in follow up examinations within the study

Exclusion Criteria:

  • Acute ischemia
  • Distal run off less than one vessel
  • Pregnancy
  • Hyperthyroidism
  • Thrombocytes <100.000/mm3 or >700.000/mm3, Leucocytes <3.000/mm3
  • Life expectancy less than two years
  • Patients not willing to enter the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00472472

Klinik für Strahlenheilkunde, Charité Campus Virchow Klinikum
Berlin, Germany, 13353
Institut für Diagnostische Radiologie und Neuroradiologie, Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität
Greifswald, Germany, 17487
Sponsors and Collaborators
University Hospital, Saarland
Principal Investigator: Jens Ricke, MD Klinik für Strahlenheilkunde, Charité Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany
Study Director: Ulrich Speck, PhD Radiologie, Campus Mitte, Charite, 10117 Berlin, Germany

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Charite Hospital, Berlin Identifier: NCT00472472     History of Changes
Other Study ID Numbers: PACCOCATH - FEM I
First Posted: May 11, 2007    Key Record Dates
Last Update Posted: June 30, 2010
Last Verified: May 2007

Keywords provided by University Hospital, Saarland:
peripheral arterial disease
drug-coated balloon

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action